Record Details

Serum homocysteine levels and sildenafil 50 mg response in young-adult male patients without vascular risk factors

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Serum homocysteine levels and sildenafil 50 mg response in young-adult male patients without vascular risk factors
 
Creator Basar, M Murad
Ozkan, Yesim
Kisa, Ucler
Simsek, Bolkan
 
Subject Erectile dysfunction
Homocysteine
Peak systolic velocity
Penile Doppler
Sildenafil
 
Description 215-220
The aim of
the present study was to investigate serum homocysteine
levels in patients with erectile dysfunction and to evaluate the relationship
between serum homocysteine levels and response to the standard 50 mg
phosphodiesterase
5 inhibitor treatment. Twenty-eight erectile dysfunction patients having normal
vascular parameter according to Penile Doppler Ultrasonography and twenty
healthy subjects were enrolled in the study. All subjects filled The
International Index of Erectile Function (IIEF) questionnaire. A total of 4-6
doses of phosphodiesterase 5 inhibitor (sildenafil 50 mg) were given to
patients. Later, they were divided into two groups as sildenafil responder and
non-responder. Serum homocysteine levels were compared in groups based on
sildenafil response. Compared with
healthy subject, higher homocysteine levels
were observed in patients with erectile dysfunction (p = 0.005), especially in
sildenafil non-responder group (p = 0.005).
There was significant negative correlation between homocysteine and IIEF scores
in group responder to sildenafil treatment (r = -0.698, p = 0.008). Mean IIEF
scores of patients with non-responder to sildenafil 50 mg were lower than those

of controls (p = 0.0001), but mean IIEF scores of patients with responders
approached values observed in control subjects
(p = 0.002). The results indicated that measurement of serum
homocysteine levels could be used as a marker for the evaluation of efficacy of
phosphodiesterase 5 inhibitor and the selection of efficacious alternative
therapies.
 
Date 2013-06-04T12:59:11Z
2013-06-04T12:59:11Z
2013-06
 
Type Article
 
Identifier 0975-0959 (Online); 0301-1208 (Print)
http://hdl.handle.net/123456789/18689
 
Language en_US
 
Rights CC Attribution-Noncommercial-No Derivative Works 2.5 India
 
Publisher NISCAIR-CSIR, India
 
Source IJBB Vol.50(3) [June 2013]